Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in family medicine
Official reprint from UpToDate® ©2015 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2015 UpToDate, Inc.
What's new in family medicine

Disclosures: David M Rind, MD Employee of UpToDate, Inc. Equity Ownership/Stock Options (Spouse): Bonfire Development Advisors [CBT (iCBT)]. H Nancy Sokol, MD Nothing to disclose. Lee Park, MD, MPH Employment (Spouse): Novartis [Age-related macular degeneration (ranibizumab)].

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy

All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Jul 2015. | This topic last updated: Aug 28, 2015.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.


Platelet-rich plasma for acute muscle injury (July 2015)

Platelet-rich plasma (PRP) injections have been touted as an effective treatment for acute muscle and tendon injuries despite scant evidence from randomized trials. The results of a recent randomized trial of 90 professional athletes with acute, MRI-confirmed hamstring injury cast further doubt on the effectiveness of PRP. In this trial, athletes treated with a single PRP injection in addition to intensive physical therapy did not return to play any faster than athletes treated with intensive physical therapy alone [1]. Re-injury rates were also similar. (See "Hamstring muscle and tendon injuries", section on 'PRP and other injections'.)

Menopausal hormone therapy and cardiovascular risk: Timing of exposure (June 2015)

Current evidence suggests that the use of menopausal hormone therapy (MHT) in the early menopausal years (<10 years from menopause) may not be associated with excess cardiovascular risk when compared with use in the later menopausal years. This has been referred to as the "timing hypothesis." Additional support for this hypothesis comes from a 2015 meta-analysis of 19 trials of oral (including the Womens Health Initiative), but not transdermal, MHT in over 40,000 postmenopausal women [2]. A subgroup analysis in women who started MHT less than 10 years after menopause showed a lower risk of coronary heart disease (CHD) compared with placebo (RR 0.52; 8 fewer cases of heart disease per 1000 women treated/year) and a lower mortality rate (RR 0.70; 6 fewer deaths per 1000 women treated/year). However, there were important limitations in this analysis; when one methodologically flawed trial was removed, the beneficial effects on CHD and mortality were no longer significant (but no adverse effects were seen). These data provide additional evidence that oral MHT use in younger postmenopausal women is not associated with excess CHD risk. (See "Menopausal hormone therapy: Benefits and risks", section on 'Younger postmenopausal women'.)

US ACIP recommendations for serogroup B meningococcal vaccination (June 2015)

In late 2014 and early 2015, the US Food and Drug Administration approved two serogroup B meningococcal vaccines (Trumenba, MenB-FHbp and Bexsero, MenB-4C). In June 2015, the Advisory Committee on Immunization Practices (ACIP) issued recommendations for serogroup B meningococcal vaccine for high-risk individuals aged 10 years or older; these include individuals with persistent complement component deficiencies, individuals with anatomic or functional asplenia, microbiologists routinely exposed to N. meningitidis isolates, and individuals at increased risk because of a serogroup B meningococcal disease outbreak [3]. These indications overlap with those for the quadrivalent meningococcal conjugate vaccine and are summarized in the table (table 1). Among patients with none of the above risk factors, the ACIP advises discussion between doctors and patients regarding vaccination against serogroup B meningococcus; routine vaccination has not been recommended [4]. (See "Meningococcal vaccines", section on 'Use in United States'.)

Comparison of commercial weight loss programs in the United States (April 2015)

A comprehensive lifestyle intervention (combined diet, exercise, and behavioral treatment) is the most important strategy for weight management. Self-help or commercial weight loss programs incorporate varying degrees of behavioral modification strategies with dietary change. A systematic review of the major available programs in the United States reported outcomes based upon a variety of measures [5]. Only two programs (Weight Watchers and Jenny Craig) reported 12-month outcomes. Compared with control groups that included education or education plus counseling, trials found an approximately 3 to 5 percent greater weight loss at 12 months for participants in the intervention arms. Longer-term outcomes are needed to better evaluate the effectiveness of other commercial programs. Commercial programs are an option for weight management of overweight or obese patients, with the recommendation that programs with clinically demonstrated efficacy be the first choice. (See "Obesity in adults: Behavioral therapy", section on 'Self-help or commercial weight loss programs'.)

Herbal products for treatment of insomnia (March 2015)

A variety of herbal products are purported to be useful for insomnia. There is little evidence from randomized controlled trials about the efficacy of many herbals, however, and for those that have been well studied (eg, valerian), there is little evidence of benefit. A meta-analysis of 14 randomized trials in over 1600 patients found no significant difference between any herbal medicine and placebo on any clinical insomnia outcome measure [6]. The majority of the trials (11 out of 14) studied valerian; chamomile, kava, and wuling were studied in one trial each. Unlike other herbals in the study, valerian was associated with a greater number of adverse events per person compared with placebo. (See "Treatment of insomnia", section on 'Over-the-counter'.)

Long duration of hot flashes (March 2015)

For many if not most menopausal women, hot flashes last considerably longer than the duration currently recommended for treatment of symptoms (maximum 4 to 5 years to minimize excess breast cancer risk). Among 1449 women with hot flashes followed longitudinally in the Study of Women Across the Nation (SWAN), the median total hot flash duration was 7.4 years, with symptoms persisting for a median of 4.5 years after the final menstrual period (FMP) [7]. Women who were premenopausal or early perimenopausal when they first experienced hot flashes had the longest total duration (>11.8 years, post-FMP median duration 9.4 years). The long duration of hot flashes raises important treatment challenges for many women, particularly those with early onset symptoms. (See "Menopausal hot flashes", section on 'Duration'.)

Revised name and diagnostic criteria for chronic fatigue syndrome (February 2015)

Diagnostic criteria for chronic fatigue syndrome have been revised (table 2) by the Institute of Medicine (IOM), which has also suggested renaming the condition as systemic exertion intolerance disease (SEID) [8]. The IOM diagnostic criteria focus on the most specific features of the disease. Symptoms should be present for at least six months and have moderate, substantial, or severe intensity at least one-half of the time. Other criteria include post-exertional malaise, sleep problems, cognitive impairment, and orthostatic-related symptoms. (See "Clinical features and diagnosis of chronic fatigue syndrome (systemic exertion intolerance disease)", section on 'Definition'.)


PCI versus CABG in patients with stable coronary artery disease (March 2015)

For patients with multivessel coronary artery disease (CAD), the optimal revascularization strategy is not known, in part because prior studies have used older generation stents. Two studies, one a randomized trial (BEST) [9] and one observational [10], found that coronary artery bypass surgery (CABG), compared with percutaneous coronary intervention with newer generation stents, is associated with a lower rate of repeat revascularization and myocardial infarction but a higher rate of stroke. We prefer CABG for many patients with multivessel CAD. (See "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'DES compared to CABG'.)


Reduced HPV vaccination rate among women who have sex with women (May 2015)

Prior research has suggested that women who have sex with women (WSW) may be less likely to initiate human papillomavirus (HPV) vaccination than their age-matched heterosexual peers. One possible reason for this discrepancy is that both WSW and their healthcare providers may erroneously believe that WSW are not at risk for HPV infection or cervical cancer. In one study of over 12,000 United States women from 2006 to 2010, of women who were aware of the HPV vaccine, only 8 percent of lesbian women had initiated vaccination compared with 28 percent of heterosexual women and 32 percent of bisexual women [11]. This study highlights the need for healthcare providers to discuss HPV vaccination with all patients. The American Academy of Pediatrics and the American College of Obstetricians and Gynecologists recommend vaccination for females and males ages 11 or 12 years of age, up to age 26. (See "Medical care of women who have sex with women", section on 'Prevention of sexually transmitted diseases'.)

Folate and cardiovascular prevention (May 2015)

Homocysteine reduction with B vitamin supplementation has not generally appeared to be beneficial in reducing cardiovascular risk. However, there have been concerns that most trials have not adequately assessed baseline folate intake in participants. A randomized trial of folic acid supplementation in Chinese adults with hypertension found a reduction in the risk of first stroke (2.7 versus 3.4 percent) [12]. This trial was performed in patients with low folate levels and with very low rates of use of statins and antiplatelet agents, and there was some suggestion that the benefit was primarily in patients with the lowest baseline levels of folate. These results are consistent with an earlier meta-analysis of folic acid supplementation and stroke that found benefits in populations with no or partial fortification of food with folic acid, and that also found greater benefit in trials in patients with low use of statins [13]. In patients coming from areas without dietary fortification, or who have diets that may have inadequate folate (eg, severe alcoholics), B-vitamin supplementation may be appropriate. (See "Overview of homocysteine", section on 'Supplementation in the general population'.)

The efficacy of an inactivated vaccine to prevent zoster (April 2015)

The live attenuated zoster vaccine reduces the risk of herpes zoster with a reported vaccine efficacy of 60 to 70 percent in adults 50 years and older, but it cannot be used in immunocompromised individuals and may have decreased efficacy in adults 70 years and older. A randomized, placebo-controlled trial evaluated the efficacy of HZ/su, an experimental recombinant inactivated zoster vaccine administered in two doses two months apart, among 15,411 adults 50 years and older [14]. After three years of follow-up, the overall vaccine efficacy against herpes zoster was 97.2 percent (95% CI 93.7-99.0), and efficacy among adults 70 years and older was similar to that seen in adults between 50 and 69 years of age. (See "Prevention of varicella-zoster virus infection: Herpes zoster", section on 'Inactivated vaccines'.)

Statins and pregnancy (April 2015)

The safety of statins in pregnancy is uncertain, but animal studies have raised concerns about fetal harm; human data are mixed. A cohort study of women enrolled in the US Medicaid program found that an association between statins and malformations was no longer present after a propensity analysis that controlled for potential confounders; pre-existing diabetes appeared to be the most important confounder [15]. However, the wide confidence intervals in this study do not exclude a potential increase (or decrease) in risk with statin therapy. We continue to recommend that statins be discontinued prior to conception if possible. (See "Statins: Actions, side effects, and administration", section on 'Risks in pregnancy and breastfeeding'.)

Exercise and vitamin D for fall prevention in older women (March 2015)

A randomized trial in home-dwelling women aged 70 to 80 years old with a history of at least one fall in the previous year evaluated the effect of exercise and/or vitamin D supplementation (800 IU per day) on fall prevention [16]. Strength and balance training did not affect the rate of falls, but halved the number of injurious falls and injured fallers, and improved muscle strength and balance compared with no exercise. Vitamin D, compared with placebo, did not prevent falls or fall-related injuries. Baseline 25-hydroxyvitamin D levels in the trial participants (26 to 28 ng/mL) were above the threshold for what is generally considered deficient. Prior meta-analyses have inconsistent findings on the effectiveness of vitamin D in fall prevention. We continue to suggest an exercise program to improve strength and balance for older adults at risk for falls. Given the low risk associated with vitamin D supplementation, and the possibility of benefit at least in adults with low baseline levels of vitamin D, we also continue to advise vitamin D supplementation. (See "Falls: Prevention in community-dwelling older persons", section on 'Exercise' and "Falls: Prevention in community-dwelling older persons", section on 'Vitamin D supplementation'.)

PCSK9 inhibitors to reduce LDL-cholesterol (March 2015)

Monoclonal antibodies that inhibit proprotein convertase subtilisin kexin 9 (anti-PCSK9 abs) reduce LDL-cholesterol levels by as much as 70 percent. In contrast with many of the other agents that have been used for lipid lowering, these agents also appear to produce substantial clinical benefits:

A meta-analysis of randomized trials in a variety of clinical situations found that anti-PCSK9 abs reduced all-cause mortality (odds ratio [OR] 0.45), cardiovascular (CV) mortality (OR 0.50), and myocardial infarction (OR 0.49) [17]. No statistical heterogeneity was found among the included trial results, suggesting that, as has been seen with statins, the relative benefits of anti-PCSK9 abs may be similar across a wide range of clinical situations and baseline risks of CV disease.

Treatment with the anti-PCSK9 abs evolocumab and alirocumab appears to result in additional reductions in risk, even in patients already on intensive or maximal statin therapy. In two open-label trials that were combined for analysis in which approximately 70 percent of participants were receiving statins, patients treated with evolocumab had a lower rate of CV events (1.0 versus 2.2 percent) [18]. In a placebo-controlled trial in which participants were receiving maximal tolerated statin therapy, patients treated with alirocumab had a lower rate of a post hoc CV composite (1.7 versus 3.3 percent); however, there was no statistically-significant reduction in the originally planned CV safety composite. Neurocognitive events, although uncommon, appeared to occur with both medications, and both require subcutaneous injection once or twice per month.

PCSK9 inhibitors are not yet generally available, but may become an important class of medication for reducing CV risk. (See "Lipid lowering with drugs other than statins and fibrates", section on 'PCSK9 inhibitors'.)

Choice of influenza vaccine formulation in patients with egg allergy (March 2015)

Most influenza vaccines are produced in an egg-based system, which has been a concern in patients with egg allergy. A number of observational studies have shown that administration of injectable inactivated influenza vaccine (IIV) containing up to 0.7 mcg ovalbumin per 0.5 mL dose is safe in patients with egg allergy. Two new observational studies have demonstrated safe administration of the intranasal live attenuated influenza vaccine (LAIV) containing <0.24 mcg ovalbumin per 0.2 mL dose in patients with egg allergy [19,20]. Influenza vaccine ovalbumin content is shown in the table (table 3). About 40 percent of patients in these studies had a history of anaphylaxis to egg and around 60 to 70 percent had asthma.

Based upon these findings and accumulating unpublished clinical experience, we recommend that all patients with egg allergy ≥6 months of age, including those with a history of anaphylaxis, receive annual immunization with an influenza vaccine according to the indications for all other patients without egg allergy. We would administer any age-appropriate, approved influenza vaccine (table 3), including the LAIV, in these patients according to the indications and contraindications outlined in the tables (table 4 and table 5). The vaccine is administered in a single dose rather than in two or more doses as a graded challenge. A 30 minute observation period is still suggested for patients with egg allergy who receive an egg-based influenza vaccine. This observation period is not necessary for those receiving an egg-free influenza vaccine. (See "Influenza vaccination in individuals with egg allergy", section on 'Safety of vaccines in patients with egg allergy' and "Influenza vaccination in individuals with egg allergy", section on 'Our approach'.)

Pneumococcal conjugate vaccine in adults ≥65 years of age (September 2014, MODIFIED March 2015)

The CAPiTA trial, which is the largest trial to assess the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar 13) in adults, compared PCV13 to placebo in approximately 85,000 immunocompetent adults ≥65 years of age in the Netherlands who had not received a pneumococcal vaccine previously [21]. The trial demonstrated 46 percent efficacy of PCV13 against vaccine-type pneumococcal pneumonia, 45 percent efficacy against vaccine-type nonbacteremic pneumococcal pneumonia, and 75 percent efficacy against vaccine-type invasive pneumococcal disease. Efficacy persisted for the duration of the trial (mean follow-up four years). However, some concern has been raised that since this trial began before PCV13 was used routinely in infants in the Netherlands, it might not answer the question of whether its use in adults is efficacious in countries that routinely vaccinate infants. (See "Pneumococcal vaccination in adults", section on 'Efficacy'.)

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been recommended for many years in the United States for all adults ≥65 years of age. In September 2014, the United States Advisory Committee on Immunization Practices (ACIP) began also recommending PCV13 for all adults ≥65 years of age [22]. The ACIP revision was prompted by results from the CAPiTA trial. Current recommendations for individuals ≥65 years of age who have not previously received either PCV13 or PPSV23 are to administer PCV13 followed 6 to 12 months later by PPSV23 (algorithm 1). In June 2015, the ACIP voted to recommend that the interval between administration of PCV13 and PPSV23 for adults ≥65 years of age be changed to one year. Formal recommendations have not yet been released. In patients who have already received PPSV23, at least one year should elapse before they are given PCV13. (See "Pneumococcal vaccination in adults", section on 'Indications'.)

Comparison among multivariate risk models to estimate 10-year CVD risk (February 2015)

A number of multivariate risk models have been developed for estimating the risk of cardiovascular disease (CVD) events in apparently healthy, asymptomatic individuals. The performance of five risk scores (1998 Framingham, 2002 ATP III, 2008 Framingham, Reynolds Risk Score, and 2013 AHA/ACC score) was evaluated by generating an estimated 10-year CVD risk within a racially-diverse population aged 50 to 74 years without baseline evidence of CVD or diabetes [23]. When comparing the predicted and observed rates of CVD over 10 years, four of the five risk scores significantly overestimated the 10-year CVD risk (between 25 and 115 percent), while the Reynolds Risk score slightly underestimated risk (3 percent underestimation). The potential for overestimation of risk should be recognized in the discussion of risk and the decision-making process regarding therapies aimed at primary prevention. (See "Estimation of cardiovascular risk in an individual patient without known cardiovascular disease", section on 'Comparison among different risk scores'.)

Varenicline for smokers who are not ready to be abstinent (February 2015)

Varenicline may be helpful for patients who smoke and who are not ready to commit to immediate cessation. A randomized trial compared varenicline with placebo for 24 weeks in 1510 smokers who were not planning to make a quit attempt within the next month but were willing to reduce smoking and attempt quitting within the next three months [24]. Compared with placebo, patients in the varenicline group had a higher continuous abstinence rate at 21 through 24 weeks and at 52 weeks. (See "Pharmacotherapy for smoking cessation in adults", section on 'Administration'.)

Additional causes of smoking mortality (February 2015)

In addition to the well-established adverse effects of smoking, a study using pooled data from five large cohorts found that, compared with never smokers, current smokers had an increased risk of mortality from renal failure, intestinal ischemia, hypertensive heart disease, any infection, breast cancer, and prostate cancer [25]. The study also found an increased risk of mortality from respiratory illnesses in addition to those previously recognized (pneumonia, influenza, COPD, and pulmonary fibrosis). The risk of mortality decreased with increasing duration of smoking cessation. (See "Benefits and risks of smoking cessation", section on 'Other'.)



Breast density and supplemental screening following mammography (May 2015)

Although multiple states in the United States have passed legislation requiring clinicians to inform women of increased breast density when found on mammography and the potential need for supplemental ultrasound screening, indications for supplemental ultrasound remain uncertain. A prospective cohort study, using data from the U.S. Breast Cancer Surveillance Consortium (BCSC), evaluated breast density and five-year breast cancer risk (by the BCSC risk model) as factors associated with interval cancer following a negative screening mammogram [26]. A high interval cancer rate (invasive cancer occurring 12 months or less after a normal mammogram) was defined as more than 1 case per 1000 mammograms. Women with heterogeneously dense breasts and a five-year breast cancer risk of 2.5 percent or greater, and women with extremely dense breasts and a five-year risk of 1.67 percent or greater, had a high interval cancer risk and were at highest risk of advanced stage disease. However, interval cancer rates were not found to be high for more than 50 percent of women with heterogeneously or extremely dense breasts. Combining increased breast density with an increased five-year risk could identify subsets of women who would be more likely to benefit from supplemental screening. (See "Breast imaging for cancer screening: Mammography and ultrasonography", section on 'Supplemental screening'.)

Interval for follow-up after benign breast biopsy (April 2015)

The appropriate interval for follow-up of patients with a benign biopsy of a palpable breast mass or radiographic breast abnormality is controversial. A study using the Breast Cancer Surveillance Consortium registry compared short-interval (3 to 8 months) with longer-interval (9 to 18 months) follow-up breast imaging screening after 17,631 benign core breast biopsies [27]. Similar rates of cancer were later detected with no significant differences in stage, tumor size, or nodal status for the short-interval and longer-interval follow-up groups. In this study, it was not determined if the initial benign biopsies in women with subsequently detected cancers represented false negatives. Short interval follow-up is likely unnecessary in women with benign breast biopsy, but if there is any uncertainty about the biopsy results, we follow-up after six months. (See "Clinical manifestations and diagnosis of a palpable breast mass", section on 'Diagnosis'.)

Interim guidelines for cervical cancer screening with primary HPV testing (February 2015)

Interim guidelines from the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology are the first US guidelines to suggest primary human papillomavirus (HPV) testing as an option for cervical cancer screening in women starting at age 25 years (table 6) [28]. This option is provided based on a randomized trial comparing primary HPV testing with cytology (Pap test) or co-testing (Pap test and HPV testing) [29]. Among women ≥25 years, primary HPV testing was more sensitive for the detection of cervical intraepithelial neoplasia (CIN) 3 or greater. However, the study is limited by having only three years of follow-up, use of a surrogate outcome (CIN3 rather than cancer), and highly structured follow up protocols that may not be feasible in practice. Given these limitations, we continue to suggest that women age <30 years not be screened for cervical cancer with primary HPV testing. (See "Screening for cervical cancer", section on 'Primary HPV testing'.)


Angiotensin receptor-neprilysin inhibitor for heart failure (July 2015)

Sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved in the United States by the Food and Drug Administration for use in patients with chronic New York Heart Association functional Class II to IV heart failure with reduced ejection fraction (HFrEF) [30]. In a randomized trial, sacubitril-valsartan reduced mortality and morbidity compared to angiotensin converting enzyme (ACE) inhibitor therapy, when used in combination with other standard heart failure therapies. Given the limited experience with sacubitril-valsartan at the present time, we suggest reserving its use, as a replacement for ACE inhibitor therapy, in patients with HFrEF with persistent symptoms on optimally titrated medical therapy including an ACE inhibitor. This recommendation is likely to evolve with time as more data become available and experience with sacubitril-valsartan develops. (See "Use of angiotensin II receptor blocker and neprilysin inhibitor in heart failure with reduced ejection fraction", section on 'Indication'.)

Coronary artery embolism as the cause of acute MI (July 2015)

Atherosclerotic coronary artery obstruction is the cause of myocardial infarction (MI) in the overwhelming majority of patients. However, no obstructive coronary atherosclerosis is found in approximately 5 percent of patients; multiple possible causes have been identified. The relationship between MI and coronary artery embolism (CE) due to atrial fibrillation (AF) was evaluated in a study of 1776 patients who presented with an acute MI [31]. The prevalence of CE was about 3 percent and atrial fibrillation was the most likely cause in three quarters of these. In patients with acute MI who do not have obstructive atherosclerotic coronary artery disease as the likely cause, undiagnosed or untreated atrial fibrillation with CE may be the explanation. (See "Myocardial infarction with no obstructive coronary atherosclerosis", section on 'Coronary artery embolism'.)

Optimal dose of aspirin after acute MI with stenting (July 2015)

The optimal dose of aspirin for patients with acute myocardial infarction (MI) who undergo stenting is not known. The TRANSLATE-ACS study evaluated outcomes in a non-randomized series of 10,123 patients who were discharged on dual antiplatelet therapy that included either 325 or 81 mg of aspirin [32]. At six months after discharge, the higher dose of aspirin was associated with an increased rate of minor bleeding not requiring hospitalization, although the rate of major adverse events was similar. We suggest that MI patients undergoing stenting be discharged on 75 to 81 mg of aspirin rather than higher doses. (See "Antiplatelet agents in acute ST elevation myocardial infarction", section on 'Aspirin for all patients'.)

Ivabradine for heart failure with reduced ejection fraction (July 2015)

Ivabradine slows the sinus rate through inhibition of the f-channels. For patients with chronic stable heart failure with left ventricular ejection fraction (LVEF) ≤35 percent, in sinus rhythm with a resting heart rate ≥70 beats per minute (bpm), and who are either on a maximum tolerated dose of a beta blocker or who have a contraindication to beta blocker use, we suggest treatment with ivabradine, as approved in the United States [33] and previously approved in Europe. In such patients, ivabradine has been shown to reduce the risk of hospitalization for worsening heart failure. (See "Use of beta blockers and ivabradine in heart failure with reduced ejection fraction", section on 'Our recommendations'.)

Oxygen not helpful in normoxic STEMI patients (June 2015)

Small studies have raised the possibility of harm from supplemental oxygen in patients with ST-elevation myocardial infarction (STEMI). In the AVOID study, 441 normoxic patients with confirmed STEMI were randomly assigned to either supplemental oxygen (8 L/min) or no oxygen [34]. The trial showed no improvement in the primary end point of a diminution in infarct size with oxygen and perhaps evidence of a larger infarct. For STEMI patients who are not hypoxic, we suggest not administering supplemental oxygen. (See "Overview of the acute management of ST elevation myocardial infarction", section on 'Oxygen'.)

Duration of dual antiplatelet therapy after coronary stenting (June 2015)

The optimal duration of dual antiplatelet therapy (DAPT) for patients who have received a drug-eluting intracoronary stent is not known. All randomized trials have found an increased rate of major bleeding and a lower rate of myocardial infarction with longer therapy. A 2015 meta-analysis confirmed a finding of an increase in all-cause mortality seen in some of the trials, although the magnitude of this increase was small [35]. For patients who have tolerated 12 months of DAPT, we suggest continuing it for at least an additional 18 months. (See "Antiplatelet therapy after coronary artery stenting", section on 'Drug-eluting stents'.)

Vorapaxar particularly beneficial in patients with recent MI and diabetes (April 2015)

Patients with diabetes and myocardial infarction (MI) are at high risk of subsequent cardiovascular events. The impact of vorapaxar, an antiplatelet agent, on these high-risk individuals was evaluated in a subgroup analysis of the TRA 2P-TIMI 50 trial, which had previously shown benefit with this agent in a broad group of patients with atherosclerotic cardiovascular disease treated with at least one other antiplatelet drug (aspirin or clopidogrel) [36]. Vorapaxar lowered the risk of cardiovascular events to a greater extent in patients with diabetes and a history of MI than those without diabetes. For patients with diabetes and a recent MI who cannot receive either ticagrelor or prasugrel (our preferred P2Y12 receptor blockers; used in combination with aspirin), and who are at low risk for bleeding, we suggest that vorapaxar be added to clopidogrel and aspirin. (See "Secondary prevention of cardiovascular disease", section on 'Vorapaxar'.)

PCI versus CABG in patients with stable coronary artery disease (March 2015)

For patients with multivessel coronary artery disease (CAD), the optimal revascularization strategy is not known, in part because prior studies have used older generation stents. Two studies, one a randomized trial (BEST) [9] and one observational [10], found that coronary artery bypass surgery (CABG), compared with percutaneous coronary intervention with newer generation stents, is associated with a lower rate of repeat revascularization and myocardial infarction but a higher rate of stroke. We prefer CABG for many patients with multivessel CAD. (See "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'DES compared to CABG'.)


SGLT2 inhibitors may predispose to DKA (July 2015)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors promote the renal excretion of glucose and thereby modestly lower elevated blood glucose levels in patients with type 2 diabetes. “Euglycemic” (usually meaning plasma glucose <250 mg/dL) diabetic ketoacidosis (DKA) has been reported in patients with type 2 diabetes taking SGLT2 inhibitors [37,38]. The absence of substantial hyperglycemia delayed recognition of DKA by both the patients and the clinicians. Thus, serum ketones should be obtained in any patient with nausea, vomiting, or malaise while taking SGLT2 inhibitors, and SGLT2 inhibitors should be discontinued if acidosis is confirmed. A warning about SGLT2 inhibitors and ketoacidosis was issued by the US Food and Drug Administration in May 2015. Given the absence of long-term efficacy and safety data, we do not recommend SGLT2 inhibitors for routine use in patients with type 2 diabetes. In addition, off-label use in type 1 diabetes is discouraged in the absence of sufficient safety data. (See "Management of persistent hyperglycemia in type 2 diabetes mellitus", section on 'SGLT2 inhibitors'.)

Liraglutide for the treatment of obesity (July 2015)

Along with diet, exercise, and behavior modification, drug therapy may be a helpful component of treatment for select patients who are overweight or obese. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, used for the treatment of type 2 diabetes. In a randomized trial in nondiabetic patients who had a body mass index (BMI) of ≥30 kg/m2 or ≥27 kg/m2 with dyslipidemia and/or hypertension, liraglutide 3 mg once daily, compared with placebo, resulted in greater mean weight loss (-8.0 versus -2.6 kg with placebo) [39]. In addition, cardiometabolic risk factors, glycated hemoglobin (A1C), and quality of life improved modestly. Gastrointestinal side effects transiently affected at least 40 percent of the liraglutide group and were the most common reason for withdrawal (6.4 percent). Liraglutide is an option for select overweight or obese patients, particularly those with type 2 diabetes, although gastrointestinal side effects (nausea, vomiting) and the need for a daily injection may limit the use of this drug. (See "Obesity in adults: Drug therapy", section on 'Liraglutide'.)

DPP-4 inhibitors for diabetes and cardiovascular safety (June 2015)

A number of trials have evaluated the cardiovascular effects of DPP-4 inhibitors. In a recent large trial, 14,735 patients with type 2 diabetes and established cardiovascular disease were randomly assigned to sitagliptin or placebo, in addition to other diabetes medications (predominantly metformin, sulfonylurea, insulin) [40]. After a median follow-up of three years, there was no difference in the primary composite cardiovascular outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), individual components of the composite, or hospitalization rate for heart failure (3.1 percent in each group). Although these data are reassuring, longer-term clinical trials are needed to definitively assess the cardiovascular safety of DPP-4 inhibitors in patients with heart disease. In addition, there are no data on cardiovascular safety in lower-risk patients. With only modest glucose-lowering effectiveness and relative expense, we do not consider DPP-4 inhibitors as options for initial therapy in the majority of patients with type 2 diabetes. (See "Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus", section on 'Cardiovascular effects'.)

Menopausal hormone therapy and risk of ovarian cancer (March 2015)

There have been concerns that menopausal hormone therapy (MHT) may be associated with an increase in ovarian cancer risk, but data are conflicting. A meta-analysis of 52 epidemiologic studies including 21,488 postmenopausal women with ovarian cancer now suggests that there is a small excess risk of ovarian cancer with MHT [41]. While the relative risk of ovarian cancer was greater in ever-users than never-users of MHT (RR 1.14), the calculated absolute excess risk associated with MHT was very low: five years of MHT use in women ages 50 to 54 years would result in about one additional ovarian cancer case per 1000 users and one ovarian cancer death per 1700 users. Given these low absolute risks, we do not consider ovarian cancer to be a major consideration when deciding to take MHT for symptomatic relief. (See "Menopausal hormone therapy: Benefits and risks", section on 'Ovarian cancer'.)

Long-term effect of antihypertensive therapy in diabetic patients (October 2014, MODIFIED March 2015)

A randomized trial and a meta-analysis have evaluated the treatment of hypertension in patients with diabetes.

The ADVANCE trial randomly assigned 11,000 diabetic patients to a fixed combination of perindopril-indapamide or placebo for approximately four years. Patients in the perindopril-indapamide group had lower rates of cardiovascular mortality (3.8 versus 4.6 percent) and all-cause mortality (7.3 versus 8.5 percent). A post-trial, open-label cohort (8500 patients) were followed for an additional six years [42]. Blood pressures between the treatment and placebo groups, which were different during the trial (135/74 versus 140/76 mmHg), became similar within six months of the trial completion and remained similar throughout the cohort phase. Compared with those originally assigned placebo, those who had received perindopril-indapamide had a lower death rate during the cohort phase (15.3 versus 16.7 percent), as well as a lower incidence of major cardiovascular events (13.3 versus 14.2 percent). Combining both the trial and cohort phases together (approximately 10 years of follow-up), all-cause mortality was lower among those in the treatment group. Thus, blood pressure lowering is associated with long-term benefits on mortality and cardiovascular disease in diabetic patients. (See "Treatment of hypertension in patients with diabetes mellitus", section on 'ADVANCE trial'.)

A meta-analysis of 40 trials examined the effect of antihypertensive therapy in 100,354 diabetic patients [43]. Follow-up ranged from six months to more than eight years, with most trials following patients for two years or longer. Compared with placebo, antihypertensive therapy reduced the rates of mortality, total cardiovascular disease, myocardial infarction, and stroke. For most outcomes, the benefit of antihypertensive therapy was limited to those whose initial systolic pressures were greater than 140 mmHg. The risk of stroke, but not other outcomes, was reduced by antihypertensive therapy in patients with lower initial systolic pressures. Some trials compared one antihypertensive drug with another. For most outcomes, no class of drugs was superior or inferior to the others. However, beta-blockers increased the risk of stroke compared with other agents. In general, the results of this meta-analysis support recommendations by UpToDate regarding the treatment of hypertension in diabetic patients. (See "Treatment of hypertension in patients with diabetes mellitus", section on 'Meta-analysis'.)


Bridging anticoagulation in patients who require warfarin interruption for surgery (July 2015)

Perioperative management of a patient receiving an anticoagulant is challenging because the risks of bleeding and thromboembolism are both increased. Not all patients require anticoagulant interruption. For those who do require interruption of their anticoagulant, the risks and benefits of bridging (use of a short-acting parenteral agent, typically a low molecular weight [LMW] heparin) have been unclear. The BRIDGE trial randomly assigned patients with atrial fibrillation to receive the LMW heparin dalteparin or placebo during warfarin interruption for surgery or an invasive procedure [44]. The risk of thromboembolism was similar in those who received dalteparin or placebo for bridging. However, patients bridged with dalteparin had a greater risk of bleeding. As a result of the BRIDGE trial, we suggest not using bridging for most individuals who require warfarin interruption. We continue to suggest bridging in certain high-risk individuals, including those with a mechanical mitral valve, thromboembolic event within the previous 12 weeks, atrial fibrillation and very high risk of stroke, recent coronary stenting, or previous thromboembolism during interruption of chronic anticoagulation. (See "Perioperative management of patients receiving anticoagulants", section on 'Whether to use bridging'.)

Weak association between citrus fruit and melanoma (July 2015)

An analysis of data from over 100,000 individuals participating in the Nurse’s Health Study found a modest 36 percent increase in melanoma risk associated with high dietary intake of citrus fruit or juice, after adjusting for known risk factors for melanoma, such as family history of melanoma, phenotypic characteristics, number of nevi, and lifetime number of blistering sunburns [45]. A potential explanation for this association is that citrus fruits are a source of psoralens, chemical compounds present in plants known to be photosensitizers. However, the results of this study need further confirmation, because, given the small increase in risk, residual confounding cannot be excluded. In the meanwhile, changes in dietary advice to the public are not warranted. (See "Risk factors for the development of melanoma", section on 'Other proposed risk factors'.)

Practice tool for managing direct oral anticoagulants (July 2015)

The direct oral anticoagulants ([DOACs]; dabigatran, rivaroxaban, apixaban, edoxaban) generally are used without routine laboratory monitoring of coagulation times; this lack of monitoring requirement is considered a major advantage over vitamin K antagonists. However, the DOACs have short half-lives, and one or two missed doses can be sufficient to eliminate their anticoagulant effect. A practice tool has been published to help clinicians ensure that patients are taking their DOAC correctly and are minimizing risks of thromboembolism and bleeding [46]. Counseling strategies are focused on minimizing gaps in therapy and avoiding medication interactions. Monitoring of renal function and treatment of hypertension are also emphasized. (See "Anticoagulation with direct thrombin inhibitors and direct factor Xa inhibitors", section on 'Comparison with heparin and warfarin'.)


Adjunctive glucocorticoids for adults with severe community-acquired pneumonia (August 2015)

For hospitalized patients with community-acquired pneumonia (CAP), glucocorticoids as adjunctive therapy to antibiotics have the potential to reduce the inflammatory response and decrease morbidity. A 2015 meta-analysis of randomized trials that included hospitalized patients with CAP suggested a modest mortality benefit for adjunctive glucocorticoids [47]. A reduction in all-cause mortality was of borderline statistical significance (relative risk [RR] 0.67, 95% CI 0.45-1.01; risk difference 2.8 percent). Rates of mechanical ventilation and acute respiratory distress syndrome were decreased, as were time to clinical stability and duration of hospitalization; rates of hyperglycemia requiring treatment increased.

Clinicians should make the decision whether or not to give glucocorticoids on a case-by-case basis, especially in patients with an elevated risk of adverse effects. Limited evidence suggests that infections caused by certain pathogens (eg, influenza virus, Aspergillus spp) may be associated with worse outcomes in the setting of glucocorticoid use [48,49]; given these concerns, we avoid adjunctive glucocorticoids if one of these pathogens is detected. (See "Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Glucocorticoids'.)

Causes of community-acquired pneumonia in adults in the United States (July 2015)

As molecular tests have become more widely available, viruses are being detected with increasing frequency in patients with community-acquired pneumonia (CAP). In the Etiology of Pneumonia in the Community (EPIC) study, an active Centers for Disease Control and Prevention (CDC) surveillance study of adults requiring hospitalization for CAP, one or more viruses were detected in 23 percent of cases, bacteria in 11 percent, bacteria and viruses in 3 percent, and fungi or mycobacteria in 1 percent; an etiology was not identified in 62 percent of cases [50]. The most commonly identified organisms were rhinovirus (in 9 percent), influenza virus (in 6 percent), and S. pneumoniae (in 5 percent). In a related study, detection of rhinovirus was associated with CAP in adults, but not in children [51]. These results add to accumulating evidence that rhinovirus is likely to play a role in CAP in adults. (See "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults", section on 'Rhinovirus' and "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults", section on 'Microbiologic diagnosis'.)

Repeat testing for women treated for trichomoniasis (July 2015)

The risk of repeat infection following treatment for a sexually transmitted infection (STI) is high. In the United States, reinfection with Trichomonas vaginalis has been reported to occur in up to 17 percent of women following treatment for an initial infection. The 2015 Centers for Disease Control and Prevention (CDC) guidelines on the management of STIs recommend that women treated for confirmed T. vaginalis infection undergo repeat testing within three months of treatment, regardless of partner treatment status [52]. Prior guidelines had only listed retesting as a consideration. The preferred diagnostic test for repeat testing is a nucleic acid amplification test (NAAT) on a vaginal swab, which can be performed as soon as two weeks after treatment. Data are insufficient to support retesting men. (See "Trichomoniasis", section on 'Follow-up'.)

Updated CDC guidelines on the management of sexually transmitted infections (June 2015)

The US Centers for Disease Control and Prevention (CDC) updated its guidelines on the management of sexually transmitted infections in June 2015 [53]. Major revisions include a lower threshold for the diagnosis of urethritis based on microscopy of a urethral specimen, a new emphasis on the role of Mycoplasma genitalium in persistent urethritis and cervicitis, preference for nucleic acid amplification-based testing for the diagnosis of Trichomonas vaginalis, and a recommendation to retest women after treatment for T. vaginalis to evaluate for reinfection. New screening recommendations include annual hepatitis C virus (HCV) testing for HIV-infected men who have sex with men and T. vaginalis testing for HIV-infected women annually and when pregnant. (See "Urethritis in adult men", section on 'Diagnostic criteria' and "Mycoplasma genitalium infection in men and women", section on 'Nongonococcal urethritis' and "Trichomoniasis", section on 'Follow-up' and "Primary care of the HIV-infected adult", section on 'Sexually transmitted infections'.)

Prevalence and clinical presentation of Borrelia miyamotoi infection (June 2015)

Borrelia miyamotoi is an emerging zoonotic pathogen that is transmitted by the same genus of ticks (eg, Ixodes scapularis, Ixodes pacificus) that transmits Borrelia burgdorferi (the agent of Lyme disease), Anaplasma phagocytophilum, and Babesia species. In one case series, B. miyamotoi was identified using polymerase chain reaction (PCR) in approximately 1 percent of specimens from 11,515 patients in the northeastern United States who presented with an acute febrile episode from April through November in 2013 and 2014 [54]. Clinical information was available for 51 patients with B. miyamotoi infection; the majority had marked headache, myalgia, arthralgia, malaise, and/or fatigue, and 24 percent were hospitalized. Diagnostic testing is not widely available, but doxycycline, which is used to treat many other tick-borne infections, is also effective against B. miyamotoi. (See "Borrelia miyamotoi infection", section on 'Clinical manifestations'.)

Antimicrobial-resistant Shigella infections in the United States (June 2015)

Antimicrobial resistance in Shigella is an increasing problem in the United States. Fluoroquinolones are typically the antibiotic class of choice in adults, and azithromycin is often used if fluoroquinolone resistance is suspected or documented. Clusters of ciprofloxacin-resistant cases, likely introduced by international travelers with subsequent domestic spread, have been reported throughout the country, and isolates with decreased susceptibility to azithromycin have caused outbreaks and sporadic cases, predominantly among men who have sex with men (MSM) [55,56]. Scattered infections with extremely drug-resistant isolates that are ciprofloxacin-resistant and have decreased susceptibility to azithromycin have also been reported [57]. These reports highlight the importance of obtaining susceptibility testing to ensure adequate efficacy of the chosen antimicrobial when managing shigellosis and emphasizing prevention measures, primarily hygiene practices around food preparation or consumption and oral or anal sex. (See "Shigella infection: Treatment and prevention in adults", section on 'Antimicrobial resistance' and "Shigella infection: Treatment and prevention in children", section on 'Antibiotic resistance'.)

Persistence of Ebola virus in bodily fluids (May 2015)

Among survivors of the 2014-2015 Ebola outbreak in West Africa, infectious virus or viral RNA has been detected from several sites (eg, urine, semen, and aqueous humor) even after it is no longer detected in blood [58-60]. Although transmission from persistent virus at these sites is possible, the risk of transmission is not well established. As an example, a patient in West Africa had detectable viral RNA in his semen 199 days after symptom onset. There was apparent transmission of Ebola virus to one, but not another, of his sexual contacts. To prevent sexual transmission of Ebola virus, the Centers for Disease Control and World Health Organization suggest Ebola survivors refrain from all sexual activity (oral, anal, vaginal) until more information on the persistence of infectious virus in convalescent patients becomes available; condoms should be used if abstinence is not possible [61,62]. (See "Epidemiology and pathogenesis of Ebola virus disease", section on 'Risk of transmission through different body fluids'.)

Early versus deferred antiretroviral therapy in treatment-naive HIV-infected individuals (May 2015)

Trials have demonstrated that antiretroviral therapy (ART) improves morbidity and mortality in HIV-infected individuals with CD4 cell counts <350 cells/microL. The benefit of ART for those with higher CD4 cell counts had been suggested by observational data but had not previously been demonstrated in a randomized trial. In the START trial, 4685 HIV-infected adults who had not previously received ART and had a CD4 cell count >500 cells/microL were randomly assigned to initiate ART immediately or when the CD4 cell count declined to <350 cells/microL [63]. After approximately three years of follow-up, an interim analysis found that the risk of the combined outcome of AIDS-related events, serious non-AIDS events (eg, major cardiovascular, renal and liver disease, and cancer), or death was reduced by 57 percent with immediate compared with deferred treatment (42 versus 96 events). These data support guidelines in the United States that recommend ART initiation in all HIV-infected patients, regardless of CD4 cell count. (See "When to initiate antiretroviral therapy in HIV-infected patients", section on 'The START trial'.)

Trends in infective endocarditis incidence in the United States (May 2015)

The epidemiology of infective endocarditis (IE) has changed over time because of changes in the prevalence of risk factors, as well as improved diagnostic tools and management. A study using the Nationwide Inpatient Sample database, which included 457,052 hospitalizations for IE in the United States between 2000 and 2011, found a steady increase in IE incidence over this time [64]. The trends in hospitalization rates overall from 2000 to 2007 and from 2008 to 2011 were not significantly different, but there was a steeper increase in hospitalization rates for streptococcal IE, specifically, after 2007. It has been postulated that this reflects reduced antimicrobial IE prophylaxis after the American College of Cardiology/American Heart Association (ACC/AHA) recommended a narrower range of indications for prophylaxis in 2007. However, in the absence of controlled data, a causal connection is uncertain. Given the available evidence, we continue to recommend an approach to IE prophylaxis consistent with the ACC/AHA guidelines. (See "Epidemiology, risk factors, and microbiology of infective endocarditis", section on 'Epidemiology' and "Antimicrobial prophylaxis for bacterial endocarditis", section on 'Trends in endocarditis incidence'.)

Ocular syphilis in the United States (April 2015)

Ocular syphilis, a potentially sight-threatening form of neurosyphilis, has been reported more frequently among HIV-infected patients compared with those without HIV. It can occur at any time after initial infection and may be associated with rash. Ocular findings typically include uveitis or optic neuritis, and the diagnosis is supported by a reactive serologic test. In the United States, an outbreak of ocular syphilis has been reported in California and Washington since December 2014; the majority of cases were among HIV-infected men who have sex with men, and several cases resulted in blindness [65]. (See "Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient", section on 'Neurosyphilis'.)

Trimethoprim-sulfamethoxazole versus clindamycin for uncomplicated skin infections (March 2015)

The efficacy of various oral antibiotic regimens for soft tissue infections in the era of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is unclear. A randomized trial at four centers in areas where community-acquired MRSA is endemic compared trimethoprim-sulfamethoxazole (TMP-SMX) and clindamycin for empiric treatment of uncomplicated skin infections (including cellulitis and/or abscess) [66]. Among 524 patients (369 adults and 155 children), the efficacy of TMP-SMX and clindamycin were comparable (cure rates 80 versus 78 percent, respectively). For most patients with nonpurulent cellulitis, however, beta-lactam antibiotics with activity against beta-hemolytic streptococci and S. aureus (eg, cephalexin or dicloxacillin) remain the first-line options for empiric treatment. (See "Cellulitis and erysipelas", section on 'Nonpurulent'.)

Interferon-free regimens to treat HCV in HIV/HCV coinfected patients (February 2015)

Patients coinfected with HIV and hepatitis C virus (HCV) traditionally had lower response rates to HCV treatment with peginterferon and ribavirin compared with individuals without HIV infection. However, with the use of direct-acting antiviral (DAA) agents in HCV treatment, HIV infection is no longer a negative predictor of response. In two studies of HIV/HCV genotype 1 coinfected individuals, sustained virological response rates to two interferon-free DAA regimens (ledipasvir-sofosbuvir or ombitasvir-paritaprevir-ritonavir and dasabuvir plus ribavirin) were greater than 90 percent, comparable to rates in populations infected with HCV alone [67,68]. The major consideration in HCV antiviral regimen selection for HIV/HCV coinfected patients is the potential for drug interactions between antiretroviral and HCV antiviral agents. (See "Treatment of hepatitis C virus infection in the HIV-infected patient", section on 'Genotype 1 infection'.)


Chlorthalidone and indapamide for hypertension treatment (July 2015)

Two meta-analyses compared thiazide-like diuretics (chlorthalidone and indapamide) with hydrochlorothiazide for the treatment of hypertension.

In a meta-analysis of 14 trials that compared the blood pressure reduction with one of three dose levels of hydrochlorothiazide (low, intermediate, high) to a corresponding dose level of one of the thiazide-like diuretics, systolic pressure reduction was greater with chlorthalidone and indapamide (by 3.6 and 5.1 mmHg, respectively) [69].

In a multiple-treatment (network) meta-analysis of 21 trials that indirectly compared thiazide-type diuretics (such as hydrochlorothiazide) with thiazide-like diuretics (such as chlorthalidone) by evaluating their efficacy against placebo or common comparator drugs, thiazide-like diuretics significantly lowered the relative risk of cardiovascular events by 12 percent and heart failure by 21 percent [70].

If a diuretic is chosen for treatment of hypertension, we suggest chlorthalidone or indapamide rather than hydrochlorothiazide.

(See "Choice of drug therapy in primary (essential) hypertension: Recommendations", section on 'Thiazide-like versus thiazide-type diuretics'.)

Combination renin-angiotensin system inhibition in diabetic patients (June 2015)

Several randomized trials that directly compared dual versus single renin-angiotensin system inhibition in diabetic patients found that dual therapy produced no benefit and an increase in adverse effects. Findings are similar in a subsequent network meta-analysis [71]. In this analysis in patients with diabetes and hypertension, dual therapy with an angiotensin-converting enzyme (ACE) inhibitor plus an angiotensin II receptor blocker (ARB) was superior to placebo in preventing end-stage renal disease, but monotherapy with either an ACE inhibitor or an ARB, also compared with placebo, produced similar benefits while dual therapy produced more adverse effects. Combination renin-angiotensin system inhibition with an ACE inhibitor and ARB or direct renin inhibitor is not recommended in diabetic patients. (See "Treatment of hypertension in patients with diabetes mellitus", section on 'Avoid combination renin-angiotensin system inhibition'.)


Limited improvement in negative symptoms in schizophrenia drug trials (June 2015)

Antipsychotic medications reduce the severity of positive symptoms in schizophrenia, such as hallucinations, delusions, and suspiciousness. Neither antipsychotic nor other medications have demonstrated comparable efficacy in the treatment of negative symptoms of the disorder, which include decreased expressiveness, apathy, flat affect, and a lack of energy. A recent meta-analysis of more than 12,000 patients with schizophrenia in over 160 randomized trials found second-generation antipsychotics, antidepressants, glutamatergic agents, and medication combinations to produce small reductions in negative symptoms compared with placebo, but not first-generation antipsychotics nor brain stimulation [72]. None of the beneficial medication effects were considered to be of a clinically significant magnitude. Clinical trials continue to test other medications as well as psychosocial interventions in the treatment of negative symptoms.(See "Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment", section on 'Drug efficacy'.)

Amyloid PET imaging in adults with and without dementia (May 2015)

The clinical utility of amyloid positron emission tomography (PET) imaging in the evaluation of patients with cognitive impairment or dementia is uncertain, in part because beta-amyloid can be demonstrated in the brains of adults with normal cognition as well as in those with clinical Alzheimer disease (AD). In a meta-analysis of 55 studies of amyloid PET in adults without dementia (n = 8694), the prevalence of a positive amyloid PET scan increased with age, ranging from 10 percent in 50-year-olds with normal cognition to 44 percent in 90-year-olds with normal cognition [73]. By contrast, among individuals with a clinical diagnosis of AD, the prevalence of a positive amyloid PET scan decreased with advancing age, ranging from 93 percent in 50-year-olds to 79 percent in 90-year-olds [74]. Although several amyloid PET tracers have been approved by regulatory bodies, their high cost, in addition to their low specificity as stand-alone tests, have thus far limited use beyond research settings. (See "Neuroimaging studies in the evaluation of dementia", section on 'Indications for functional and molecular imaging'.)

Late-onset generalized anxiety disorder (April 2015)

Generalized anxiety disorder (GAD) is typically thought of as having an early onset, rarely first presenting in older adults. A recent, prospective study of a large, representative sample of French adults aged 65 years and over, who did not meet criteria for GAD at baseline, found the disorder to have an incidence of 8.4 percent over the subsequent 12-year period [75]. In 80 percent of cases, the occurrence was the first episode of GAD. Predictors of incident GAD included being female, poverty, recent adverse life events, chronic physical or mental illness, and parental/familial factors. Increased awareness and recognition of late-onset GAD would enable more patients to receive effective treatments for the disorder, including cognitive behavioral therapy and selective serotonin reuptake inhibitors. (See "Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis", section on 'Course'.)

Treatment of extracranial carotid or vertebral artery dissection (March 2015)

Antithrombotic therapy with either anticoagulation or antiplatelet drugs has long been used as treatment for ischemic stroke and transient ischemic attack (TIA) caused by cervical arterial dissection, but the two therapies had never been compared in a randomized trial. This situation changed with publication of the open-label, assessor-blind CADISS pilot trial, which enrolled 250 subjects with extracranial carotid or vertebral dissection and randomly assigned them to antiplatelet or anticoagulant treatment for three months [76,77]. At the end of this period, there was no significant difference between the two treatment groups; ipsilateral ischemic stroke occurred in 3 of 126 patients (2 percent) in the antiplatelet group and 1 of 124 patients (1 percent) in the anticoagulant group. There were no deaths in either group and one major bleeding event in the anticoagulation group.

Because of the low stroke rate and rarity of outcome events, the CADISS trial was not able to establish which treatment is superior. However, in the absence of a clear advantage for anticoagulation, most UpToDate authors now favor aspirin over anticoagulation for treating cervical artery dissection because it is less complicated to administer and generally safer. However, some experts prefer anticoagulation rather than aspirin in this setting. Antithrombotic treatment must be delayed until 24 hours after thrombolytic therapy but can be started immediately for patients who are not treated with thrombolytic therapy. (See "Spontaneous cerebral and cervical artery dissection: Treatment and prognosis", section on 'Antithrombotic therapy'.)


Extended anticoagulation for pulmonary embolism (July 2015)

Patients with unprovoked pulmonary embolism (PE) are at high risk of recurrence once anticoagulation is discontinued. Whether anticoagulation beyond a conventional course is beneficial was investigated in a randomized trial of 371 adult patients with a first episode of symptomatic unprovoked PE who had completed six months of warfarin therapy [78]. Rates of recurrent thrombosis were seven times higher in patients treated with placebo compared with those who continued anticoagulant therapy. However, rates of major bleeding were higher with extended anticoagulation, and once discontinued, the benefit of reduced recurrence was not maintained. These results reflect similar data derived from patients with deep venous thrombosis treated with extended anticoagulant therapy. Clinicians should continue to evaluate patients with unprovoked venous thromboembolism on an individual basis and weigh the benefits of extended anticoagulation against the risk of major bleeding. (See "Rationale and indications for indefinite anticoagulation in patients with venous thromboembolism", section on 'Recurrence with and without anticoagulation'.)

Limited occult cancer screening for venous thromboembolism (June 2015)

Occult cancer is associated with venous thromboembolism (VTE). However, evidence to support a specific evaluation strategy is limited. In a randomized trial of 854 patients with a first unprovoked episode of VTE, a limited strategy for the evaluation of cancer (basic laboratory testing, chest radiography, and breast, cervical, and prostate cancer screening) was compared with a more comprehensive strategy (the limited strategy plus CT of the abdomen and pelvis) [79]. Both strategies identified a low incidence of cancer (approximately 4 percent) and cancer-related mortality at one year was low (1 percent) in both groups. Thus, the addition of CT of the abdomen and pelvis did not improve cancer detection, and the study supports our practice of adopting a limited approach to evaluation in patients with a first episode of unprovoked VTE. (See "Evaluating patients with established venous thromboembolism for acquired and inherited risk factors", section on 'First episode of uncomplicated unprovoked VTE'.)

Warning about use of non-prescription asthma treatments (April 2015)

The US Food and Drug Administration (FDA) released a consumer warning about the potential health risks of over-the-counter (OTC) homeopathic products for asthma [80]. The efficacy and safety of OTC products are not evaluated by the FDA. In addition, there is evidence that some non-prescription therapies, such as racemic epinephrine inhaler (sold as Asthmanefrin) and systemic ephedrine (sold as Bronkaid and Primatene tablets), are less effective than standard therapies for asthma and have a higher rate of side effects. Thus, OTC products are not recommended for the routine care of asthma, particularly acute asthma symptoms. These warnings are an important reminder for clinicians to ask their patients about use of OTC products. (See "Asthma in children younger than 12 years: Rescue treatment for acute symptoms", section on 'Nonstandard therapies' and "Alternative and experimental agents for the treatment of asthma", section on 'Risks associated with inhaled epinephrine' and "Alternative and experimental agents for the treatment of asthma", section on 'Homeopathic agents' and "Homeopathy", section on 'Specific diseases'.)


Arthroscopic surgery for knee osteoarthritis (June 2015)

Arthroscopic knee surgery, including partial meniscectomy and/or debridement, has been widely used as a therapeutic intervention for symptomatic osteoarthritis of the knee, with or without a meniscal tear, although efficacy data are lacking. A meta-analysis identified nine randomized trials comparing arthroscopic knee surgery (involving partial meniscectomy, debridement, or both) with non-surgical treatments in middle-aged and older patients with knee pain, with or without radiographic evidence of knee osteoarthritis [81]. There was a clinically insignificant difference in pain in favor of arthroscopic knee surgery at three and six months of follow-up, but not at later times points up to 24 months. There was no significant benefit of knee arthroscopy on physical function. Adverse events after knee arthroscopy included deep venous thrombosis (4 per 1000 arthroscopies), infection, pulmonary embolism, and death. These findings support the lack of clinical efficacy of arthroscopic knee surgery in the treatment of knee pain from osteoarthritis. (See "Overview of surgical therapy of knee and hip osteoarthritis", section on 'Osteoarthritis plus a meniscal tear'.)

Possible association of giant cell arteritis with varicella zoster virus (March 2015)

The etiology of giant cell arteritis (GCA) remains unknown, although various infectious causes have been considered as triggering events. One of the largest studies to evaluate the relationship between varicella zoster virus (VZV) and GCA included temporal artery (TA) biopsies from 82 pathologically-confirmed GCA patients and 13 TA biopsies from healthy controls [82]. VZV antigen was found in 74 percent of pathologically-confirmed GCA TAs versus 8 percent of normal TAs. The majority of biopsies showing GCA contained VZV antigen in skip areas that correlated with adjacent GCA pathology. However, direct pathogenetic evidence of a causal role of VZV in GCA is lacking. (See "Pathogenesis of giant cell (temporal) arteritis", section on 'Etiology and pathogenesis'.)


Safety concerns regarding hysteroscopic sterilization (July 2015)

Safety concerns have been raised about female sterilization via hysteroscopic placement of micro-inserts into the fallopian tubes. A prospective study of this procedure reported that, at five years, up to 38 percent of women reported recurrent menstrual irregularities and up to 5 percent reported recurrent pelvic pain [83]. Between 2002 and 2015, the US Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database received 5093 adverse effects reports related to this device, including over 4700 related to menstrual abnormalities or pelvic pain [84]. In September 2015, the FDA will convene a meeting of the Obstetrics and Gynecology Devices Panel to review the safety and effectiveness of hysteroscopic sterilization. (See "Hysteroscopic sterilization", section on 'FDA panel'.)

Improving uptake of long-acting reversible contraceptives (July 2015)

Long-acting reversible contraceptives (LARC), which include implants and intrauterine devices, are the most effective reversible methods to prevent pregnancy. Interventions that increase LARC use lower the rate of unintended pregnancy. In a trial of 1500 women who were randomly assigned to receive either standardized counseling for LARC or routine contraceptive counseling, standardized counseling resulted in increased LARC use and a reduction in unintended pregnancies (8 versus 15 percent) [85]. Introduction of affordable LARC methods in the state of Colorado from 2009 to 2013 was associated with an approximately 40 percent reduction in teen birth and abortion rates compared with previous years [86]. These data add further support to our suggestion to use LARC for women who desire reversible contraception. (See "Overview of contraception", section on 'Effectiveness'.)


Frozen oocyte use impacts live birth rate (August 2015)

Use of donor oocytes (eggs) in assisted reproductive technology has allowed women unable to conceive with their own eggs the opportunity to achieve pregnancy. The use of frozen oocytes is more convenient and less costly compared with fresh oocytes because the donor and recipient don't have to be hormonally synchronized and frozen eggs can be shipped anywhere. Although initial studies reported equivalent pregnancy and live birth rates for donor egg transfers, a study of over 11,000 oocyte donation cycles, including 20 percent using frozen eggs, reported the live birth rate per transfer for frozen donor oocytes was lower than the live birth rate for fresh donor oocytes (47 versus 56 percent) [87]. Despite the possible discrepancy in live birth rate, the improved efficiency and lower cost of cryopreserved donor oocytes makes their use a reasonable and attractive option. (See "Management of infertility and pregnancy in women of advanced age", section on 'Oocyte or embryo donation'.)

Prescription medications during pregnancy (August 2015)

Concerns have been raised regarding the frequency with which medication is prescribed during pregnancy, especially for those drugs that may have adverse outcomes for the mother or her fetus. In a study of over one million pregnant women in the United States Medicaid program, nearly 40 percent were prescribed a potentially harmful medication (category D, most commonly codeine and hydrocodone) and 5 percent were prescribed a medication contraindicated during pregnancy (category X, most commonly hormonal contraceptives that were prescribed prior to the diagnosis of pregnancy) [88]. Overall, 83 percent were dispensed at least one medication of any kind (most commonly antibiotic or antifungal agents). While medication can be safely used in pregnancy, the lowest risk option is to avoid drug exposure if possible. When medication is to be taken, the risks and benefits must be discussed, particularly for medications with harmful potential, such as addiction. (See "Initial prenatal assessment and first trimester prenatal care", section on 'Medications commonly used in pregnancy'.)

Use of venlafaxine during early pregnancy and risk of birth defects (June 2015)

Venlafaxine is often used as an alternative to selective serotonin reuptake inhibitors for treating antenatal depression, but the risk of birth defects with venlafaxine is not clear due to inconsistent findings across small observational studies. A study of national registries from multiple countries identified infants who were exposed to venlafaxine during the first trimester (n>2700) and infants who were not exposed (n>2,100,000); the analyses controlled for several potential confounding factors, such as maternal age, smoking, diabetes, and use of other medications (eg, antiepileptics) [89]. The risk of major birth defects was comparable for the two groups, as was the specific risk for cardiac defects. However, this study did not address other perinatal risks, such as preterm birth or hypertension, which have been associated with venlafaxine in other studies. (See "Risks of antidepressants during pregnancy: Drugs other than selective serotonin reuptake inhibitors", section on 'Teratogenicity'.)

Expectant management of mild preeclampsia near term (June 2015)

The optimum time for delivery of women with preeclampsia without features of severe disease and stable maternal and fetal conditions at 34 to 36 weeks of gestation is uncertain. The recent randomized HYPITAT-II trial confirmed findings from observational studies showing that most patients with late-onset mild preeclampsia managed expectantly will reach term without progressing to severe disease or developing an adverse outcome [90]. Newborns benefited from the extra time in utero: the rate of respiratory distress syndrome was 70 percent less with expectant management compared with immediate delivery. Mild preeclampsia with onset at 34 to 36 weeks can be managed expectantly to enable further fetal growth and maturation. Delivery is indicated at 37 weeks. (See "Preeclampsia: Management and prognosis", section on 'Preeclampsia without features of severe disease'.)

Gestational age apps (June 2015)

Electronic techniques, such as apps available for download to smart phones, are generally more accurate for determining gestational age than mechanical wheels. However, a high proportion of gestational age apps are also inaccurate [91]. Clinicians and patients should be aware of this possibility when using a gestational age app, and clinicians should test the accuracy of the app they use. UpToDate provides calculators that determine the estimated date of delivery and current gestational age. (See "Prenatal assessment of gestational age and estimated date of delivery", section on 'Calculator'.)

Nicotine replacement therapy during pregnancy (May 2015)

Cigarette smoking during pregnancy is associated with adverse pregnancy outcomes. Nicotine replacement therapy has had limited use in pregnant women because of concerns regarding potential adverse fetal effects and limited evidence supporting efficacy. In a retrospective study of nearly 200,000 children born in the United Kingdom, the rates of major congenital anomalies were not statistically different among infants of women using nicotine replacement therapy, women who smoked, and women who did not use either [92]. System-specific analysis reported an increased risk of respiratory anomalies in the nicotine replacement-exposed children, but the absolute risk was 3 per 1000 births, and based on 10 exposed cases out of 157 children with respiratory anomalies. Given the known benefits of smoking cessation during pregnancy, nicotine replacement therapy appears to be a reasonable treatment option for pregnant women who wish to stop smoking. (See "Cigarette smoking and pregnancy", section on 'Nicotine replacement'.)

Iron supplementation in pregnancy (April 2015)

The total maternal iron requirement associated with pregnancy is about 1000 mg. For this reason, many clinicians prescribe a prenatal vitamin with iron for pregnant women. In a 2015 systematic review for the US Preventive Services Task Force, routine iron supplementation in pregnancy resulted in a 50 to 80 percent reduction in the frequency of iron deficiency anemia at term, but effects on other pregnancy outcomes were inconsistent [93]. We suggest prenatal vitamins with iron for pregnant women for prevention of maternal iron deficiency anemia. (See "Nutrition in pregnancy".)

False positive Down syndrome screening tests (April 2015)

Noninvasive prenatal Down syndrome screening using cell free DNA results in lower false positive and false negative rates than conventional aneuploidy screening tests. In a recent study of Down syndrome screening in an unselected population including almost 16,000 women, the false positive rates of cell free DNA and conventional screening were 0.1 and 5 percent, respectively, and false negative rates were 0 and 21 percent, respectively [94]. False positive results can be due to factors such as maternal mosaicism, maternal tumors, maternal copy number variants, vanishing twins, confined placental mosaicism, or a failure of the complex bioinformatics necessary to generate a result [95-102]. Despite the low false positive rate with cell free DNA screening, confirmatory diagnostic testing (genetic amniocentesis or chorionic villus sampling) is mandatory after a screen positive result. (See "Noninvasive prenatal testing using cell-free nucleic acids in maternal blood", section on 'Trisomy 21, 18, 13'.)

Safety of inhaled long-acting beta agonist/glucocorticoid for asthma during pregnancy (February 2015)

An important clinical question for pregnant women with asthma is whether using a combination long-acting beta-agonist (LABA) plus inhaled glucocorticoid confers an increased risk for adverse fetal outcomes, compared with monotherapy using a higher dose of the inhaled glucocorticoid. In a study of 1302 pregnant women with asthma, the risk for a major congenital malformation was not increased when a LABA plus low dose inhaled glucocorticoid was compared with a medium dose inhaled glucocorticoid, or when a LABA plus medium-dose inhaled glucocorticoid was compared with a high-dose inhaled glucocorticoid [103]. (See "Management of asthma during pregnancy", section on 'Long-acting beta-adrenergic agents'.)


Ease of use of different epinephrine autoinjectors for anaphylaxis (July 2015)

Epinephrine autoinjectors can be life saving for patients with serious allergies, but even with specific training, many people have trouble using the various devices properly. A randomized trial of mothers of food-allergic children, tested in simulated anaphylaxis scenarios, suggested that the Auvi-Q device, a rectangular cassette that has audible instructions to guide the user through the injection process, was easier to use than non-audible pen devices [104]. When prescribing an epinephrine autoinjector, ease of use, cost, the need for multiple injectors, and patient facility with self-injection should all be considered. (See "Prescribing epinephrine for anaphylaxis self-treatment", section on 'Ease of use'.)

Outcomes of infants with inconclusive newborn screening for cystic fibrosis (July 2015)

CFTR-related metabolic syndrome (CRMS) describes infants with an equivocal diagnosis following newborn screening for cystic fibrosis (CF). These infants usually have elevated levels of immunoreactive trypsinogen, but inconclusive results of subsequent sweat and DNA testing. The natural history of infants with CRMS is unclear. Now, a small study of infants with an initial diagnosis of CRMS reports that 48 percent were later diagnosed with CF, most within the first year of life [105]. Affected individuals had a somewhat milder CF phenotype compared with infants who were diagnosed with CF by newborn screening. These findings highlight the importance of longitudinal clinical and laboratory follow-up of infants with CRMS. (See "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'CFTR-related metabolic syndrome'.)

Updated recommendations for pediatric head lice (May 2015)

Pediculosis capitis is a common condition that can lead to physical discomfort and social stigmatization. An update to the 2010 clinical report on head lice published by the American Academy of Pediatrics incorporates new therapies (spinosad and topical ivermectin), clarifies diagnosis and treatment protocols, and provides guidance for the management of children with pediculosis capitis in the school setting [106]. Examples of major points in the update include recommendations that no child should be excluded from school because of head lice or nits and that pyrethroids remain reasonable first-line therapies for primary treatment of pediculosis capitis in communities where resistance to pyrethroids is unproven. (See "Pediculosis capitis", section on 'Pediculicide selection'.)

Diagnostic accuracy of serial ultrasounds for pediatric appendicitis (April 2015)

In pediatric patients whose initial ultrasound is equivocal for the diagnosis of appendicitis and who have persistent findings, repeat physical examination and a second ultrasound has good diagnostic accuracy and can markedly reduce the use of computed tomography (CT). A prospective observational study of 294 children undergoing acute evaluation for abdominal pain (38 percent with appendicitis) evaluated a protocol stratifying children into three paths: serial physical examination, surgical consultation, and repeat ultrasound if the initial ultrasound was equivocal; discharge home if the initial ultrasound showed a normal appendix; and surgical consultation if the initial ultrasound was positive for appendicitis [107]. This strategy, consistent with our approach, achieved a sensitivity of 97 percent and a specificity of 91 percent; CT was performed in four patients. (See "Acute appendicitis in children: Diagnostic imaging", section on 'Imaging approach'.)

Early introduction of peanuts in high-risk infants (March 2015)

Previous guidelines recommended delayed introduction of highly allergenic solid foods (eg, eggs, peanuts, tree nuts, dairy products other than cow's milk, fish, and shellfish) for the purpose of preventing allergic disease in high-risk infants. However, evidence from observational studies suggested this practice was not effective and may lead to an increased incidence of food allergies.

The Learning Early about Peanut Allergy (LEAP) trial is the first randomized trial to show benefit of early introduction of a major food allergen [108]. In this study, introduction of peanut at 4 to 11 months of age rather than avoidance until 60 months of age in children at high risk for peanut allergy due to severe eczema and/or egg allergy decreased the risk of developing peanut allergy. The rate of peanut allergy in the consumption group compared with the avoidance group was 1.9 versus 13.7 percent in children who were skin prick test-negative, and 10.6 versus 35.3 percent in children who were skin prick test-positive (wheal 1 to 4 mm). Exclusion criteria included a skin prick test wheal >4 mm or a positive baseline oral food challenge to peanut.

These findings indicate that past recommendations to delay introduction of highly allergenic foods were appropriately rescinded. Interim guidance regarding peanut introduction in infants with manifestations of atopic disease similar to those in the LEAP study is given in a consensus communication by an international group of allergy organizations [109]. (See "Introducing formula and solid foods to infants at risk for allergic disease", section on 'Introduction of solid foods to high-risk infants'.)

National and ethnic variability in head circumference standards (March 2015)

The World Health Organization (WHO) Child Growth Standards were developed with data from the WHO Multicenter Growth Reference Study (MGRS) to describe normal growth in children younger than five years of age. However, it may be inappropriate to use a single head circumference standard for children from different countries or ethnic groups. A systematic review compared the mean head circumferences from the WHO MGRS with the mean head circumferences from a variety of studies in 55 countries or ethnic groups [110]. The mean head circumferences in some groups were sufficiently different from those of the MGRS that use of the WHO growth standards would result in misclassification of microcephaly or macrocephaly. When available, local head circumference standards may be preferable to the WHO growth standards. (See "Microcephaly in infants and children: Etiology and evaluation", section on 'Head circumference charts' and "Macrocephaly in infants and children: Etiology and evaluation", section on 'Head circumference charts'.)

Azithromycin and infantile pyloric stenosis (March 2015)

Treatment with erythromycin during the first few weeks of life is an established risk factor for developing infantile hypertrophic pyloric stenosis (IHPS). A large study further defines the magnitude of that risk, and reveals that azithromycin also is a risk factor for IHPS. In a retrospective cohort of more than one million infants, the risk of developing IHPS was increased more than ten-fold for exposure to erythromycin or azithromycin during the first two weeks of life, and more than three-fold for exposure between two and six weeks of age [111]. Exposure after six weeks of age was not associated with IHPS risk. (See "Infantile hypertrophic pyloric stenosis", section on 'Macrolide antibiotics'.)

Morphine is not more effective than ibuprofen for post-tonsillectomy pain in children (March 2015)

There is growing evidence that opioid medication should not be used as first-line analgesic therapy for post-tonsillectomy pain, particularly in children with underlying obstructive sleep apnea (OSA). A randomized trial found ibuprofen and acetaminophen to be as effective as morphine and acetaminophen for postoperative pain management in children undergoing tonsillectomy for OSA [112]. In addition, children treated with morphine had increased episodes of postoperative desaturation compared with baseline, whereas those who received ibuprofen had improvement in oxygen saturation postoperatively. Caution should be used in prescribing opioids post-tonsillectomy in patients with underlying OSA. (See "Tonsillectomy (with or without adenoidectomy) in children: Postoperative care and complications", section on 'Pain'.)

Strict cognitive rest associated with more symptoms in children with concussions (February 2015)

Strict cognitive rest, including avoidance of reading, video games, loud music, and screen time (computer, tablet, television, or smart phone), limitation of social activities, and absence from school, has been advocated as a primary treatment for pediatric concussion. However, evidence for this approach is sparse. In a trial of 99 patients aged 11 to 22 years who were diagnosed with a concussion after pediatric emergency department evaluation (36 percent with loss of consciousness), all subjects reduced physical activity and one group was assigned to strict cognitive rest for five days while the other was assigned to usual care (one to two days of rest followed by gradual return to full cognitive activities) [113]. Strict cognitive rest was associated with significantly more daily reported postconcussive symptoms during the 10 days of follow-up, while there were no differences in neurocognitive function or balance outcomes at three and 10 days after injury. Thus, strict cognitive rest was harmful in this trial. We suggest an individualized approach to cognitive rest, in which patients are instructed to avoid mental activities that worsen symptoms and are followed closely by a clinician with expertise in managing concussions. (See "Concussion in children and adolescents: Management", section on 'Cognitive rest'.)

Oat cereal for thickening infant bottle feeds (February 2015)

For healthy infants with problematic gastroesophageal reflux who are bottle-fed, thickening feeds with infant cereal slightly improves symptoms. Although rice cereal has traditionally been used for this purpose, oat cereal is now preferred because of concerns about possible contamination of rice cereal with arsenic [114-116]. The US Food and Drug Administration (FDA) is investigating to determine if there are clinically significant traces of arsenic in rice cereal. (See "Gastroesophageal reflux in infants", section on 'Thickening feeds'.)


Sleep problems in children with ADHD (March 2015)

Attention deficit hyperactivity disorder (ADHD) is associated with sleep problems, particularly initiating and maintaining sleep. A randomized trial suggests that ADHD symptoms improve with treatment of comorbid sleep problems [117]. Children with ADHD and a moderate to severe sleep disorder were assigned to usual care or two sleep consultations and a follow-up phone call with a trained clinician; most of the children were receiving ADHD medications (predominantly methylphenidate). At the three- and six-month follow-up, children in the intervention group had modest improvements in ADHD symptoms and teacher-reported behavior. These findings highlight the importance of treating coexisting sleep problems in children with ADHD. (See "Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis", section on 'Treatment of coexisting conditions'.)


Effectiveness of pertussis vaccine in infants (May 2015)

Infants younger than 12 months have the highest incidence of pertussis and pertussis-related complications, including death. In a large case-control study, having received ≥1 dose of pertussis vaccine was associated with a 72 percent reduction in the risk of death and a 31 percent reduction in the risk of hospitalization in infants ≥6 weeks of age (the minimum age for the first dose of pertussis vaccine) [118]. However, 64 percent of the deaths occurred in infants younger than six weeks. These findings highlight the importance of timely pertussis immunization for infants, as well as maternal immunization during pregnancy and immunization of the infant’s close contacts, as recommended by the Global Pertussis Initiative [119]. (See "Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age", section on 'Efficacy and effectiveness' and "Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination' and "Bordetella pertussis infection in adolescents and adults: Treatment and prevention", section on 'Tdap booster'.)


Acetaminophen alone not effective in reducing neonatal pain (August 2015)

Acetaminophen (paracetamol) has been used in the management of mild to moderate procedural and postoperative neonatal pain. However, a recent systematic review of randomized trials found that acetaminophen alone was not more effective than placebo in preventing or reducing pain associated with heel lance or eye examination in newborns [120]. As a result, we do not recommend using acetaminophen as the sole agent in newborns to reduce pain from painful procedures. (See "Prevention and treatment of neonatal pain", section on 'Lack of efficacy'.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Hamilton B, Tol JL, Almusa E, et al. Platelet-rich plasma does not enhance return to play in hamstring injuries: a randomised controlled trial. Br J Sports Med 2015; 49:943.
  2. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 3:CD002229.
  3. Folaranmi T, Rubin L, Martin SW, et al. Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:608.
  4. (Accessed on June 25, 2015).
  5. Gudzune KA, Doshi RS, Mehta AK, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med 2015; 162:501.
  6. Leach MJ, Page AT. Herbal medicine for insomnia: A systematic review and meta-analysis. Sleep Med Rev 2014; 24C:1.
  7. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175:531.
  8. IOM (Institute of Medicine). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press; 2015 (Accessed on February 12, 2015).
  9. Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372:1204.
  10. Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med 2015; 372:1213.
  11. Agénor M, Peitzmeier S, Gordon AR, et al. Sexual Orientation Identity Disparities in Awareness and Initiation of the Human Papillomavirus Vaccine Among U.S. Women and Girls: A National Survey. Ann Intern Med 2015; 163:99.
  12. Huo Y, Li J, Qin X, et al. Efficacy of folic acid supplementation in primary prevention of stroke among adults with hypertension in China. JAMA 2015.
  13. Huo Y, Qin X, Wang J, et al. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis. Int J Clin Pract 2012; 66:544.
  14. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087.
  15. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ 2015; 350:h1035.
  16. Uusi-Rasi K, Patil R, Karinkanta S, et al. Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. JAMA Intern Med 2015; 175:703.
  17. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:40.
  18. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500.
  19. Des Roches A, Samaan K, Graham F, et al. Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. J Allergy Clin Immunol Pract 2015; 3:138.
  20. Turner PJ, Southern J, Andrews NJ, et al. Safety of live attenuated influenza vaccine in atopic children with egg allergy. J Allergy Clin Immunol 2015; 136:376.
  21. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114.
  22. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63:822.
  23. DeFilippis AP, Young R, Carrubba CJ, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med 2015; 162:266.
  24. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA 2015; 313:687.
  25. Carter BD, Abnet CC, Feskanich D, et al. Smoking and mortality--beyond established causes. N Engl J Med 2015; 372:631.
  26. Kerlikowske K, Weiwei Z, Tosteson ANA, et al. Identifying women with dense breasts at high risk for interval cancer. Ann Intern Med 2015.
  27. Johnson JM, Johnson AK, O'Meara ES, et al. Breast cancer detection with short-interval follow-up compared with return to annual screening in patients with benign stereotactic or US-guided breast biopsy results. Radiology 2015; 275:54.
  28. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol 2015; 125:330.
  29. Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol 2015; 136:189.
  30. (Accessed on July 22, 2015).
  31. Shibata T, Kawakami S, Noguchi T, et al. Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism. Circulation 2015; 132:241.
  32. Xian Y, Wang TY, McCoy LA, et al. Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circulation 2015; 132:174.
  33. (Accessed on June 25, 2015).
  34. Stub D, Smith K, Bernard S, et al. Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction. Circulation 2015; 131:2143.
  35. Spencer FA, Prasad M, Vandvik PO, et al. Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:118.
  36. Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 2015; 131:1047.
  37. Peters AL, Buschur EO, Buse JB, et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015.
  38. Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab 2015; 100:2849.
  39. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373:11.
  40. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373:232.
  41. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385:1835.
  42. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371:1392.
  43. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313:603.
  44. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015.
  45. Wu S, Han J, Feskanich D, et al. Citrus Consumption and Risk of Cutaneous Malignant Melanoma. J Clin Oncol 2015; 33:2500.
  46. Gladstone DJ, Geerts WH, Douketis J, et al. How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med 2015.
  47. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 2015.
  48. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam JS, Lim WS. Effect of Corticosteroid Therapy on Influenza-Related Mortality: A Systematic Review and Meta-analysis. J Infect Dis 2015; 212:183.
  49. Parody R, Martino R, Sánchez F, et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 2009; 84:571.
  50. Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.
  51. Self WH, Williams DJ, Zhu Y, et al. Respiratory Viral Detection in Children and Adults: Comparing Asymptomatic Controls and Patients With Community-Acquired Pneumonia. J Infect Dis 2015.
  52. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
  53. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.
  54. Molloy PJ, Telford SR 3rd, Chowdri HR, et al. Borrelia miyamotoi Disease in the Northeastern United States: A Case Series. Ann Intern Med 2015; 163:91.
  55. Bowen A, Hurd J, Hoover C, et al. Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015. MMWR Morb Mortal Wkly Rep 2015; 64:318.
  56. Bowen A, Eikmeier D, Talley P, et al. Notes from the Field: Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:597.
  57. CDC Health Advisory. Ciprofloxacin- and Azithromycin-Nonsusceptible Shigellosis in the United States.
  58. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371:2394.
  59. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. N Engl J Med 2015; 372:2423.
  60. Christie A, Davies-Wayne GJ, Cordier-Lasalle T, et al. Possible sexual transmission of Ebola virus - Liberia, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:479.
  61. World Health Organization. Sexual transmission of the Ebola Virus: evidence and knowledge gaps (Accessed on April 17, 2015).
  62. Centers for Disease Control. Ebola virus disease: transmission. (Accessed on October 29, 2014).
  63. INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015.
  64. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 2015; 65:2070.
  65. Centers for Disease Control. Clinical advisory: ocular syphilis in the United States. (Accessed on April 07, 2015).
  66. Miller LG, Daum RS, Creech CB, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. N Engl J Med 2015; 372:1093.
  67. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232.
  68. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223.
  69. Roush GC, Ernst ME, Kostis JB, et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65:1041.
  70. Olde Engberink RH, Frenkel WJ, van den Bogaard B, et al. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 2015; 65:1033.
  71. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 2015; 385:2047.
  72. Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull 2015; 41:892.
  73. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015; 313:1924.
  74. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015; 313:1939.
  75. Zhang X, Norton J, Carrière I, et al. Risk factors for late-onset generalized anxiety disorder: results from a 12-year prospective cohort (the ESPRIT study). Transl Psychiatry 2015; 5:e536.
  76. CADISS trial investigators, Markus HS, Hayter E, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 2015; 14:361.
  77. Kasner SE. CADISS: a feasibility trial that answered its question. Lancet Neurol 2015; 14:342.
  78. Couturaud F, Sanchez O, Pernod G, et al. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA 2015; 314:31.
  79. Carrier M, Lazo-Langner A, Shivakumar S, et al. Screening for Occult Cancer in Unprovoked Venous Thromboembolism. N Engl J Med 2015.
  80. Over-the-Counter Asthma Products Labeled as Homeopathic: FDA Statement - Consumer Warning About Potential Health Risks.
  81. Thorlund JB, Juhl CB, Roos EM, Lohmander LS. Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms. BMJ 2015; 350:h2747.
  82. Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology 2015; 84:1948.
  83. Chudnoff SG, Nichols JE Jr, Levie M. Hysteroscopic Essure Inserts for Permanent Contraception: Extended Follow-Up Results of a Phase III Multicenter International Study. J Minim Invasive Gynecol 2015.
  84. (Accessed on July 17, 2015).
  85. Harper CC, Rocca CH, Thompson KM, et al. Reductions in pregnancy rates in the USA with long-acting reversible contraception: a cluster randomised trial. Lancet 2015.
  86. Reducing unintended teen pregnancy in Colorado (Accessed on July 06, 2015).
  87. Kushnir VA, Barad DH, Albertini DF, et al. Outcomes of Fresh and Cryopreserved Oocyte Donation. JAMA 2015; 314:623.
  88. Palmsten K, Hernández-Díaz S, Chambers CD, et al. The most commonly dispensed prescription medications among pregnant women enrolled in the US Medicaid program. Obstet Gynecol 2015; 126:465.
  89. Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ 2015; 350:h1798.
  90. Broekhuijsen K, van Baaren GJ, van Pampus MG, et al. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial. Lancet 2015; 385:2492.
  91. Chyjek K, Farag S, Chen KT. Rating Pregnancy Wheel Applications Using the APPLICATIONS Scoring System. Obstet Gynecol 2015; 125:1478.
  92. Dhalwani NN, Szatkowski L, Coleman T, et al. Nicotine replacement therapy in pregnancy and major congenital anomalies in offspring. Pediatrics 2015; 135:859.
  93. Cantor AG, Bougatsos C, Dana T, et al. Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 162:566.
  94. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015; 372:1589.
  95. Lau TK, Cheung SW, Lo PS, et al. Non-invasive prenatal testing for fetal chromosomal abnormalities by low-coverage whole-genome sequencing of maternal plasma DNA: review of 1982 consecutive cases in a single center. Ultrasound Obstet Gynecol 2014; 43:254.
  96. Lau TK, Jiang FM, Stevenson RJ, et al. Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service. Prenat Diagn 2013; 33:602.
  97. Wang Y, Chen Y, Tian F, et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem 2014; 60:251.
  98. Osborne CM, Hardisty E, Devers P, et al. Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat Diagn 2013; 33:609.
  99. Grati FR, Malvestiti F, Ferreira JC, et al. Fetoplacental mosaicism: potential implications for false-positive and false-negative noninvasive prenatal screening results. Genet Med 2014; 16:620.
  100. Mao J, Wang T, Wang BJ, et al. Confined placental origin of the circulating cell free fetal DNA revealed by a discordant non-invasive prenatal test result in a trisomy 18 pregnancy. Clin Chim Acta 2014; 433:190.
  101. Snyder MW, Simmons LE, Kitzman JO, et al. Copy-number variation and false positive prenatal aneuploidy screening results. N Engl J Med 2015; 372:1639.
  102. Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol 2015; 45:530.
  103. Eltonsy S, Forget A, Beauchesne MF, Blais L. Risk of congenital malformations for asthmatic pregnant women using a long-acting β₂-agonist and inhaled corticosteroid combination versus higher-dose inhaled corticosteroid monotherapy. J Allergy Clin Immunol 2015; 135:123.
  104. Umasunthar T, Procktor A, Hodes M, et al. Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial. Allergy 2015; 70:855.
  105. Groves T, Robinson P, Wiley V, Fitzgerald DA. Long-term outcomes of children with intermediate sweat chloride values in infancy. J Pediatr 2015; 166:1469.
  106. Devore CD, Schutze GE, Council on School Health and Committee on Infectious Diseases, American Academy of Pediatrics. Head lice. Pediatrics 2015; 135:e1355.
  107. Schuh S, Chan K, Langer JC, et al. Properties of serial ultrasound clinical diagnostic pathway in suspected appendicitis and related computed tomography use. Acad Emerg Med 2015; 22:406.
  108. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372:803.
  109. Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-Risk Infants. (Accessed on June 02, 2015).
  110. Natale V, Rajagopalan A. Worldwide variation in human growth and the World Health Organization growth standards: a systematic review. BMJ Open 2014; 4:e003735.
  111. Eberly MD, Eide MB, Thompson JL, Nylund CM. Azithromycin in early infancy and pyloric stenosis. Pediatrics 2015; 135:483.
  112. Kelly LE, Sommer DD, Ramakrishna J, et al. Morphine or Ibuprofen for post-tonsillectomy analgesia: a randomized trial. Pediatrics 2015; 135:307.
  113. Thomas DG, Apps JN, Hoffmann RG, et al. Benefits of strict rest after acute concussion: a randomized controlled trial. Pediatrics 2015; 135:213.
  114. US Food and Drug Administration. Questions & Answers: Arsenic in rice and rice products. (Accessed on October 29, 2014).
  115. American Academy of Pediatrics, AAP group offers advice to reduce infants’ exposure to arsenic in rice, AAP News 2014; 35:13. Available at: (Accessed on February 09, 2015).
  116. Hojsak I, Braegger C, Bronsky J, et al. Arsenic in rice: a cause for concern. J Pediatr Gastroenterol Nutr 2015; 60:142.
  117. Hiscock H, Sciberras E, Mensah F, et al. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial. BMJ 2015; 350:h68.
  118. Tiwari TS, Baughman AL, Clark TA. First pertussis vaccine dose and prevention of infant mortality. Pediatrics 2015; 135:990.
  119. Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics 2015; 135:e1475.
  120. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for prevention or treatment of pain in newborns. Cochrane Database Syst Rev 2015; 6:CD011219.
Topic 8349 Version 4662.0

Topic Outline



All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.